While the #1 cause of death in both men and women in the United States is heart disease, the #2 cause of death is cancer.

Cancer is the result of many factors, which I have discussed in detail in the both the ITIRD model [https://www.flemingmethod.com/] and a series of three presentations I provided in 2023 [https://www.flemingmethod.com/answers], including 9 specific causes for cancer resulting from the SARS-CoV-2 infection and the spike protein ITIR producing the ITIRD of CANCER, found in both the virus and the genetic vaccines.

​

The number 1 cause of death among women is in fact, heart disease with the 2 cause being cancer - specifically breast cancer followed by lung cancer.

​

As I mentioned previously, beginning in the contributions tab, I was approached in the late 1990s and asked if I would be willing to look at nuclear imaging applications for diagnosing breast cancer.

​

The approach which I described previously and which is described in the publications at the bottom of this page, incorporated my knowledge as a physicist and nuclear cardiologist to develop a protocol, which would take advantage of TWO critical aspects of cancers. The first being an increase in metabolic activity, resulting in the second - an increase in regional blood flow required to provide increased nutritional support for the overly metabolically active tissue & the removal of wastes from the metabolic byproducts of the cancer and precancerous tissues.

​

The information obtained also provided new insights into why secondary cancers appear following removal of the primary cancer as well as laying the foundation for future non-toxic cancer treatments. This knowledge was gleaned from my retrospective analysis of FMTVDM imaging studies which demonstrated that primary cancers (abnormal tissue which grows uncontrollably and spreads to other parts of the body) and tumors (an abnormal growth of tissue) were inhibiting the growth of smaller secondary cancers; inhibition that stopped following removal of the primary (larger) cancer.

​

My research work also allowed me to harvest breast cancer tissue and grow the tissue for further investigation. For those knowledgeable in the field of harvesting and maintaining cancer cell lines, you understand that this is extremely hard to do with almost all efforts being fraught with failure. This failure appears to be related to the increased metabolic and waste removal requirements needed to maintain a viable cancer.

​

It is important to note that my efforts to grow breast cancer all failed using the originally prescribed breast cancer culture media. It was only because I had harvested more breast tissue from one of the women I was working with than we had culture media for, that I was left with the decision of either destroying the extra tissue or plate it on an alternative growth media. It was the second growth media that worked. Something that had not been tried before, or to the best of my knowledge, since.

​

This page includes published research discussing some of these findings, including:

​

1) FMTVDM's measurement of changes in breast tissue, differentiating early transitional changes from early breast cancer, as well as later stages of breast cancer.

​

2) Confirmation of the Gompertz, Laird theories on changes in tissue metabolism and growth, which were confirmed by FMTVDM.

​

3) A comparison of FMTVDM with mammography and other anatomic tests, which are dependent upon (a) the expectation(s) of the person interpreting the results, (b) sufficient tissue death to result in calcium release from the dead cells, which can then show up on radiographic images as calcium deposits, (c) sufficient increases in density of images to suggest a possible cancer, and (d) positioning of the patient for anatomic studies.

​

4) Changes in measured regions of breast cancer before and following treatments, including the measurements associated with the inhibition of secondary cancers by the larger primary cancers.

​

5) The ability to measure other tissue changes found during the breast cancer imaging, including thyroid, pulmonary, thymus and other tissue abnormalities.

​

6) Since FMTVDM is able to quantify regional blood flow and metabolism, like heart disease, FMTVDM can be used Theranostically - the ability to both diagnostically define the state of someone's health/disease, but also determine by measurement whether the treatment (independent of what the treatment is) is working; or not.

​

As should be obvious from #5, but I will state it here for the record, FMTVDM is useful for any type of cancer AND as you will see in the next drop down tab (page), it is useful for infections as well. More on that in the next page.

​

Finally, before I add some of my published research papers, you may also notice that during my decades of working with FMTVDM, some of my terminology has changed as my work continued to evolve, and since I invented and developed all of this, deciding what I want to call something is one of the perks. 

 

One of the most striking examples is the term Breast Enhanced Scintigraphy Test (B.E.S.T.).

​

B.E.S.T. was simply the first term I used to distinguish FMTVDM heart imaging from breast imaging.

​

Something else you will see in this research, is that men also develop breast cancer and with the absence of tissue between the male breast and the chest wall where the breast cancer can metastasize (spread to other parts of the body), men with breast cancer have a lower survival rate. You will see the results of FMTVDM (BEST) imaging in men as well as women.

 

It also distinguished what I was doing from the non-pharmacologicaly enhanced breast cancer imaging known as resting Miraluma which was neither quantitative nor capable of distinguishing changes in regional blood flow and/or metabolism.

​

Now to some of the published research.